Aruachan Vesga Sandra, González Manuel, Rojas Danis M, Ospina Javier, Duque-Varela Santiago, Castaño Andrés Ángel
Unidad de Estudios Clínicos, Clínica IMAT Oncomédica Auna, Montería, Colombia.
Servicio de Oncología Clínica, Clínica IMAT Oncomédica Auna, Montería, Colombia.
Biomedica. 2025 Mar 28;45(1):51-63. doi: 10.7705/biomedica.7239.
Introduction. Spending on drugs to treat cancer will increase by 9-12% annually until 2025. For health systems in high and middle-income countries –such as Colombia– and with an increasing trend of new cancer cases, clinical research can contribute to the efficient use of the system resources available without undermining the timeliness and quality of healthcare. Objective. To calculate the savings generated to the Colombian health system by the implementation of externally funded clinical trials for cancer. Materials and methods. We conducted an observational, longitudinal, descriptive, and retrospective study analyzing participant’s medical records of clinical trials between 2016 and 2022 at the Clínica IMAT Oncomédica Auna, Colombia. Results. The total savings to the health system for external financing of oncology drugs was USD $1,526,320, and the monthly weighted average savings per patient was USD $3,257. The participation of breast cancer patients in randomized controlled clinical trials (n = 138) accounted for 24% (USD $369,363) of the total savings. Participants with clinical stage IV and III accounted for 41.7% (USD $636,475) and 31.06% (USD $473,159), respectively, of the total savings to the general social security health system in Colombia from external financing of oncological drugs. Conclusion. The participation of cancer patients in clinical trials mitigated costs to the Colombian health system, especially in women with breast cancer and in those patients with clinical stage IV of the disease.
引言。到2025年，用于治疗癌症的药物支出将以每年9%至12%的速度增长。对于高收入和中等收入国家（如哥伦比亚）的卫生系统而言，随着癌症新病例呈上升趋势，临床研究有助于在不影响医疗及时性和质量的前提下，有效利用现有系统资源。目的。计算通过实施外部资助的癌症临床试验为哥伦比亚卫生系统节省的费用。材料和方法。我们开展了一项观察性、纵向、描述性和回顾性研究，分析了2016年至2022年期间哥伦比亚IMAT Oncomédica Auna诊所癌症临床试验参与者的病历。结果。卫生系统在肿瘤药物外部融资方面的总节省金额为1,526,320美元，每位患者每月的加权平均节省金额为3,257美元。乳腺癌患者参与随机对照临床试验（n = 138）占总节省金额的24%（369,363美元）。临床IV期和III期参与者分别占哥伦比亚一般社会保障卫生系统在肿瘤药物外部融资总节省金额的41.7%（636,475美元）和31.06%（473,159美元）。结论。癌症患者参与临床试验减轻了哥伦比亚卫生系统的成本，尤其是乳腺癌女性患者和疾病临床IV期患者。
